MVM Life Science Partners is a Venture Capital firm that invests in technologies and products for the life science and healthcare markets. MVM has teams in London and Boston.
16th December 2011
Richter Announces EMA Approval for PregLem's Esmya
Gedeon Richter Plc. announces that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for Esmya® as pre-operative treatment of moderate to severe symptoms of uterine fibroids.
Read this article
13th December 2011
Tarsa Therapeutics Targets 2012 NDA Submission for its Ostora
Tarsa Therapeutics has confirmed that it is planning to submit a New Drug Application to the Food and Drug Administration in the second half of 2012 for OSTORA™, the company’s oral recombinant salmon calcitonin tablet for the treatment of postmenopausal osteoporosis.
Read this article
Richter Announces EMA Approval for PregLem's Esmya
Gedeon Richter Plc. announces that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for Esmya® as pre-operative treatment of moderate to severe symptoms of uterine fibroids.
Read this article
13th December 2011
Tarsa Therapeutics Targets 2012 NDA Submission for its Ostora
Tarsa Therapeutics has confirmed that it is planning to submit a New Drug Application to the Food and Drug Administration in the second half of 2012 for OSTORA™, the company’s oral recombinant salmon calcitonin tablet for the treatment of postmenopausal osteoporosis.
Read this article
